Tagged with Asia-Pacific

Asia-Pacific The latest from Southeast Asian pharma, including soaring output in Singapore, tax breaks for research in Indonesia, Thai firm Factorytalk’s UK expansion, and the potential for a Russian COVID-19 vaccine manufacturing facility in the Philippines.   Singapore Factory Output Surges At Fastest Pace In Nine Years On Pharma Boost (Business…

Asia-Pacific Robert Hall of Hong Kong-based executive recruitment specialist Ardent Search highlights the key traits and experiences that Asian biotech and medtech firms considering an initial public offering (IPO) should look for in a chief financial officer (CFO).   Hiring an experienced healthtech CFO can be challenging, with demand exceeding supply.…

Roundup The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy can kickstart the domestic Filipino pharma industry.   Alvotech and DKSH have expanded their partnership to commercialize six new biosimilar…

Opinion Robert Hall of Ardent Search, an executive search boutique specialised in the life sciences and healthcare sectors, highlights the five key points for recruiters and pharma companies to consider when hiring market access professionals to work in Asia.   Whether it is an established or a developing market, access is…

Gilead With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and CEO Daniel O’Day and Gilead vice-president and general manager of the Asia 5 region (Singapore, South Korea, Hong Kong, Taiwan, Malaysia) Andrew Hexter are determined to stress…

Japan Dr Ken-ichiro Hata, representative director and chairperson of Japan’s Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation’s mandate, how Japan has been able to cultivate one of the world’s most mature regenerative medicine ecosystems, and highlights key challenges including regulatory misalignment across Asia and the need for better manufacturing…

Asia-Pacific In an exclusive and wide-ranging interview, Takeda APAC SVP Thomas Willemsen outlines his strategy for bringing the company’s specialty pharma portfolio to the diverse group of countries that make up the APAC region, the potential significance of Takeda’s upcoming dengue vaccine, and what Asia’s contribution to global healthcare and life…

Asia-Pacific Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the significance of Asian markets being the first to approve remdesivir as a COVID-19 treatment, and the importance of public-private partnerships…

Singapore A roundup of some of the most significant healthcare and life science stories from across Singapore and the Asia-Pacific region, including the ongoing hunt for a COVID-19 vaccine and a significant acquisition for Korean Celltrion.   Coronavirus vaccine: Singapore scientists discover 5 antibodies that can combat COVID-19 https://www.businesstoday.in/sectors/pharma/coronavirus-vaccine-singapore-scientists-discover-5-antibodies-that-can-combat-covid/story/407214.html A team…

Coronavirus The 2019 Wuhan coronavirus outbreak has seen a surge in demand for protective masks as publics across the world seek to protect themselves from infection. Manufacturers of the masks have seen their stocks boom, but supply is outstripping demand and hoarding practices may leave healthcare professionals on the frontline of…

Asia-Pacific Ai Hua Ong, Asia-Pacific company group chairman of Janssen, the Pharmaceutical Companies of Johnson & Johnson, looks back at the tremendous progress the pharmaceutical industry has made in the Asia-Pacific region over the last ten years and highlights how the industry needs to adapt to meet emergent challenges.   By…

China Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic one, since his appointment in 2016. He also discusses the value of Pierre Fabre’s oncology portfolio for the region and…